in ,

Bristol Myers Squibb buys MyoKardia for $ 13.1 billion

(New York) The American pharmaceutical company Bristol Myers Squibb (BMS) announced on Monday its intention to buy the company MyoKardia, which specializes in treatments for cardiovascular disease, for $ 13.1 billion.

Posted Oct 5, 2020 at 8:31 am

Agence France-Presse

BMS shows special interest in Mavacamten, a drug currently under clinical trial for obstructive hypertrophic cardiomyopathies, a chronic heart disease with high mortality, a statement released.

Written by Rahis

Leave a Reply

Your email address will not be published. Required fields are marked *

Facing the crisis | Celsius would be amazed

A quarter of Ubisoft employees report "bad behavior at work"